Viral hepatitis B (HBV) and hepatitis C (HCV) pose a significant overall health challenge globally and if untreated, each viruses lead to serious liver harm resulting in liver cirrhosis and cancer. Though HBV has a vaccine, HCV has none at the moment. The danger of drug resistance, combined with the higher price of present therapies, tends to make it a necessity for price-successful therapeutics to be found and created. The current surge in interest in Health-related Cannabis has led to interest in evaluating and validating the therapeutic potentials of Cannabis and its metabolites against several illnesses which includes viruses. Preliminary screening of cannabidiol (CBD) revealed that CBD is active against HCV but not against HBV in vitro. CBD inhibited HCV replication by 86.four% at a single concentration of 10 μM with EC50 of three.163 μM in a dose-response assay. These findings recommend that CBD could be additional created and employed therapeutically against HCV.
Cannabidiol exhibited in vitro activity against viral hepatitis C. Abbreviations Applied: CB2: Cannabis receptor two, CBD: Cannabidiol, DNA: Deoxyribonucleic acid, HBV: Hepatitis B virus, HCV: Hepatitis C virus, HIV/AIDS: Human immunodeficiency virus/acquired immune deficiency syndrome, HSC: Hepatic stellate cells, MTS: three-(four,five-dimethylthiazol-two-yl)-five-(three-carboxymethoxyphenyl)-two-(four-sulfophenyl)-2Htetrazolium, PCR: Polymerase chain reaction.
Copyright © 2018 Elsevier B.V. All rights reserved.
PMID: 28250664 PMCID: PMC5330095 DOI: 10.4103/0974-8490.199780
Lowe HI1, Toyang NJtwo, McLaughlin Wthree.